Neetij Krishnan

Neetij Krishnan

Auto-generated profile, based on publicly available information

Neetij Krishnan

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026 in Science Advances
Verified
Journal Article
Closed access
LLLaura López-Hernández
Laura López-Hernández
SCStephanie J. Crowley
Stephanie J. Crowley
SCSara Cea-Sánchez
Sara Cea-Sánchez
RARicardo de Arellano
Ricardo de Arellano
NKNeetij Krishnan
Neetij Krishnan
GMGonzalo Millán-Zambrano
Gonzalo Millán-Zambrano
Acute myeloid leukemia (AML) is driven by genetic alterations and non-mutational mechanisms that disrupt normal hematopoiesis and support leukemic cell survival. While the mutational landscape of AML is well characterized, the non-genetic processes sustaining leukemic maintenance remain less understood. Using human AML cells and murine models, we identify BCL2-associated transcription factor 1 (BCLAF1) as a key regulator of leukemic progression through control of mRNA processing. BCLAF1 physically associates with core spliceosome components and regulates alternative splicing programs in leukemic cells. Mechanistically, BCLAF1 is required for productive splicing of activating transcription factor 4 (ATF4) mRNA, thereby sustaining ATF4 protein levels and downstream metabolic gene expression programs. Loss of BCLAF1 reduces ATF4 levels, leading to impaired de novo amino acid biosynthesis and increased sensitivity to venetoclax. Together, these findings uncover a previously unrecognized mechanism linking RNA splicing control to metabolic adaptation in AML, identifying BCLAF1 as a potential therapeutic vulnerability.